May 13, 2020 / 10:03 PM / 18 days ago

BRIEF-Immunogen Announces Initial Data From Forward II Study Evaluating Mirvetuximab Soravtansine In Combination With Avastin In Recurrent Ovarian Cancer

May 13 (Reuters) - ImmunoGen Inc:

* IMMUNOGEN ANNOUNCES INITIAL DATA FROM FORWARD II STUDY EVALUATING MIRVETUXIMAB SORAVTANSINE IN COMBINATION WITH AVASTIN® IN RECURRENT OVARIAN CANCER, REGARDLESS OF PLATINUM STATUS

* IMMUNOGEN - COMBINATION DEMONSTRATES PROMISING ANTI-TUMOR ACTIVITY WITH CONFIRMED OVERALL RESPONSE RATE OF >60% IN PATIENTS WITH HIGH FRΑ EXPRESSIO Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below